Difference between revisions of "Normative:Antibody"
Jump to navigation
Jump to search
(new addition) |
(formatting) |
||
| Line 1: | Line 1: | ||
==Normative== | ==Normative== | ||
=== Encyclopaedic information === | === Encyclopaedic information === | ||
Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic and therapeutic agents for COVID-19. | Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic and therapeutic agents for COVID-19. | ||
| Line 32: | Line 26: | ||
* neutralizing antibody: 96 | * neutralizing antibody: 96 | ||
* antibody titer: 582 | * antibody titer: 582 | ||
Latest revision as of 18:45, 7 March 2022
Normative
Encyclopaedic information
Neutralizing antibodies directed at the receptor-binding domain of SARS-CoV-2 spike protein have been evaluated as prophylactic and therapeutic agents for COVID-19.
Examples
Transplant recipients who are hospitalized with mild to moderate COVID-19 may be considered for anti-SARS-CoV-2 monoclonal antibodies that are available through expanded access programs.
Source: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
Collocations
- monoclonal antibodies
- anti-SARS-CoV-2 antibodies
- neutralizing antibodies
- antibody response
- antibody titers
Keyness
- antibody: 150
- monoclonal antibody: 45
- anti-sars-cov-2 monoclonal antibody: 50
- neutralizing antibody: 96
- antibody titer: 582